A transcriptome-wide association study identifies novel blood-based gene biomarker candidates for Alzheimer's disease risk

Hum Mol Genet. 2021 Dec 27;31(2):289-299. doi: 10.1093/hmg/ddab229.

Abstract

Alzheimer's disease (ad) adversely affects the health, quality of life and independence of patients. There is a critical need to identify novel blood gene biomarkers for ad risk assessment. We performed a transcriptome-wide association study to identify biomarker candidates for ad risk. We leveraged two sets of gene expression prediction models of blood developed using different reference panels and modeling strategies. By applying the prediction models to a meta-GWAS including 71 880 (proxy) cases and 383 378 (proxy) controls, we identified significant associations of genetically determined expression of 108 genes in blood with ad risk. Of these, 15 genes were differentially expressed between ad patients and controls with concordant directions in measured expression data. With evidence from the analyses based on both genetic instruments and directly measured expression levels, this study identifies 15 genes with strong support as biomarkers in blood for ad risk, which may enhance ad risk assessment and mechanism-focused studies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / genetics
  • Genetic Markers
  • Genome-Wide Association Study
  • Humans
  • Polymorphism, Single Nucleotide / genetics
  • Quality of Life
  • Transcriptome / genetics

Substances

  • Genetic Markers